Document is current
Any future updates will be listed below
-
Authors
Li, Jun http://orcid.org/0000-0002-1171-7141
Liu, Wei
Mojumdar, Kamalika http://orcid.org/0000-0003-3420-4258
Kim, Hong
Zhou, Zhicheng
Ju, Zhenlin
Kumar, Shwetha V.
Ng, Patrick Kwok-Shing
Chen, Han
Davies, Michael A. http://orcid.org/0000-0002-0977-0912
Lu, Yiling
Akbani, Rehan http://orcid.org/0000-0003-2686-7721
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Liang, Han http://orcid.org/0000-0001-7633-286X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA209851, U01CA217842)
- License Information
-
More Information
Article History
Received: 4 October 2023
Accepted: 5 August 2024
First Online: 3 September 2024
Competing interests
: M.A.D. has been a consultant to Roche/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance and ABM Therapeutics and he has been the PI of research grants to MD Anderson from Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon and ABM Therapeutics. R.A. is a bioinformatics consultant for the University of Houston. G.B.M. is a scientific advisory board member or consultant for AstraZeneca, Chrysalis Biotechnology, GSK, ImmunoMET, Ionis, Lilly, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen, Tarveda, Turbine and Zentalis Pharmaceuticals, has stocks, options or financial considerations with Catena Pharmaceuticals, ImmunoMet, SignalChem and Tarveda and has licensed the HRD assay to Myriad Genetics and DSP patents to Nanostring. H.L. is a shareholder and advisor for Precision Scientific. The other authors declare no competing interests.
